nejm glp 1 Expanding Clinical Benefits for GLP-1–Receptor Agonists 𝗧𝗵𝗲 𝗘𝗳𝗳𝗲𝗰𝘁 𝗼𝗳 𝗚𝗟𝗣-𝟭 𝗥𝗲𝗰𝗲𝗽𝘁𝗼𝗿

Saxenda (liraglutide) Saxenda is a GLP-1 medication appropriate for adults who: Have obesity (BMI of 30 or above) Have overweight (BMI of 27 or above) along with a weight-related comorbid condition like high blood pressure, type 2 diabetes, or high cholesterol or triglycerides It is also approved for children ages 12 and above who weigh more than 132 pounds and are considered obese

But a wave of new research and biotech innovation suggests a seismic shift may be coming one that could redefine how hair loss is treated and perhaps make it one of the next major medical breakthroughs on par with GLP-1 therapies in metabolic health

It is not switching products

Levels are solid, you're feeling great, and you're ready to absolutely crush it in the gym

Our study further demonstrates that the risks of significant adverse events such as aspiration are low